反応式
Cl[C:2]1[CH:3]=[CH:4][C:5]([N+:15]([O-:17])=[O:16])=[C:6]([N:8]2[CH2:13][CH2:12][CH:11]([CH3:14])[CH2:10][CH2:9]2)[CH:7]=1.[NH:18]1[CH2:23][CH2:22][NH:21][CH2:20][CH2:19]1>CO.ClCCl>[CH3:14][CH:11]1[CH2:12][CH2:13][N:8]([C:6]2[CH:7]=[C:2]([N:18]3[CH2:23][CH2:22][NH:21][CH2:20][CH2:19]3)[CH:3]=[CH:4][C:5]=2[N+:15]([O-:17])=[O:16])[CH2:9][CH2:10]1参加物
4
実験手順
The procedure of Example 4, step (b) was followed using 460 mg (1.81 mmol) of 1-(5-chloro-2-nitro-phenyl)-4-methyl-piperidine (as prepared in the Example 12, step (a)) and 3.12 g (36.2 mmol) of piperazine for 24 h to afford, after chromatography on a 20-g silica SPE column with 0-10% MeOH-dichloromethane, 518 mg (94%) of the title compound as an orange resin: Mass spectrum (ESI, m/z): Calcd. for C16H24N4O2, 305.2 (M+H), found 305.1.
後処理
- customto afford
出典と根拠
- ORDレコード
- ord-f7f76e6e12184c7b9f2fa13578520345
- 出典データセット
- uspto-grants-2010_04
- 特許番号
- US07705042B2
関連ノート
読み込み中…